Incorporating Prognostic Scoring Systems in Treatment Decisions for Lower-Risk MDS

EP: 1.Overview of Low-Risk MDS: Clinical Hallmarks and Current Treatments

Now Viewing

EP: 2.Incorporating Prognostic Scoring Systems in Treatment Decisions for Lower-Risk MDS

EP: 3.The Role of Luspatercept as First-Line Treatment in Lower-Risk MDS

EP: 4.Impact of Improved Hemoglobin Levels on Patient Well-being and Quality of Life

EP: 5.Approaches to Initiating and Adjusting Luspatercept Dosing

EP: 6.Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)

EP: 7.Advancing the Treatment Landscape for Lower-Risk MDS: Unmet Needs and Future Directions

EP: 8.Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating Agents

Video content above is prompted by the following question(s):

• When making treatment decisions for lower-risk MDS patients, how do you incorporate prognostic scoring systems like IPSS-R and IPSS-M into your decision-making process?
  • Please elaborate on how these scoring systems influence your choice between luspatercept and other available therapies for managing anemia in these patients?
• Please discuss the how mutational burden impacts response and duration of response in the COMMANDS trial.